Kapitalforeningen Accunia Invest
Meddelelse om at der er foretaget ændringer i prospekterne for:
• Accunia Invest EUR CLO Opportunity KL, ACAECO, DK0060804052
• Accunia Invest EUR CLO Invest Grade DKK, ACACIGDKK, DK0060804136
• Accunia Invest European High Yield (KL), ACKEHY, DK0061149036
Der er foretaget følgende ændring:
• Som følge af den nye forordning om bæredygtighedsrelaterede oplysninger (SFDR), der træder i kraft den 10.marts 2021, er der indsat et afsnit med bæredygtighedsrelaterede oplysninger.
Kontaktperson:
Direktør Caspar Møller, tlf. +45 3332 7070.
Yderligere oplysninger om Kapitalforeningen Accunia Invest findes på www.accunia-invest.dk.
Store Regnegade 5, 1, 1110 København K, tlf. 33 32 70 70
contact@accunia.com
Attachments
- §62-dok - EuroCLO.IG - AccInvKF (mar'21)
- §62-dok - EuroCLO.OPP - AccInvKF (mar'21)
- §62-dok - EuroHY - AccInvKF (mar'21)
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About Globenewswire
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
Orrön Energy AB7.1.2026 08:00:00 CET | Press release
Orrön Energy secures grid connections for six projects in the UK and obtains municipal approval for additional projects in Germany
Orion Oyj7.1.2026 07:30:00 CET | Press release
Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)
FLSmidth A/S7.1.2026 07:24:58 CET | Press release
FLSmidth: Transactions under share buy-back programme
Basilea Pharmaceutica AG, Allschwil7.1.2026 07:15:00 CET | Press release
Basilea and Prokaryotics enter collaboration to develop a novel broad-spectrum antifungal for the treatment of severe invasive infections
Vivoryon Therapeutics N.V.7.1.2026 07:00:00 CET | Press release
Vivoryon Therapeutics N.V. to Attend and Present in Upcoming Conferences
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom